Repligen Corporation $RGEN Shares Sold by American Century Companies Inc.

Key Points

• American Century Companies Inc. has reduced its stake in Repligen Corporation by 9.8%, now holding about 0.45% of the company's shares, valued at approximately $32.33 million.
• Institutional investors and hedge funds collectively own 97.64% of Repligen's stock, indicating strong institutional interest in the company.
• Analysts have a consensus rating of "Moderate Buy" for Repligen with an average target price of $169.45, despite a recent downgrade from "buy" to "hold" by Wall Street Zen.

American Century Companies Inc. cut its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 9.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 254,115 shares of the biotechnology company's stock after selling 27,543 shares during the quarter. American Century Companies Inc. owned approximately 0.45% of Repligen worth $32,334,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the period. Conestoga Capital Advisors LLC lifted its position in shares of Repligen by 3.4% during the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after buying an additional 32,665 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after buying an additional 594,189 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock valued at $79,574,000 after buying an additional 43,946 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Repligen by 28.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 580,485 shares of the biotechnology company's stock valued at $83,556,000 after buying an additional 126,913 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Stock Down 1.3%

Shares of RGEN traded down $1.61 during mid-day trading on Wednesday, hitting $118.88. 499,746 shares of the company traded hands, compared to its average volume of 785,214. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $6.69 billion, a PE ratio of -475.50, a price-to-earnings-growth ratio of 2.22 and a beta of 1.05. The business has a 50 day moving average of $121.58 and a 200 day moving average of $130.72.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter last year, the company earned $0.40 EPS. The business's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several analyst reports. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company decreased their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. Finally, Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.